Inhaled treprostinil and pulmonary arterial hypertension

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 1115-1124

  Nadler, Samuel T ^a   Edelman, Jeffrey D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

6MWD; Bosentan; Prostacyclin; Pulmonary arterial hypertension; Treprostinil

Indexed keywords

ADENOSINE; AMBRISENTAN; ANOREXIGENIC AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; THROMBOXANE; UNIPROST;

AMINOTRANSFERASE BLOOD LEVEL; CONTINUOUS INFUSION; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; JAW PAIN; LUNG CIRCULATION; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOMATOLOGY;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY;

EID: 80051882781     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S14777     Document Type: Review

References (79)

1. Hoeper M. Defnition, classification and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009;30:369-375.
2. D'Alonzo GF, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med. 1991;115:343-349.
3. Thenappan T, Shah S, Rich S, Tian L, Archer S, Gomberg-Maitland M. Contemporary survival in patients with pulmonary arterial hypertension: A reappraisal of the NIH risk stratifcation equation. Eur Respir J. 2010;35:1079-1087.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med. 2006;173:1023-1030.
5. Peacock A, Murphy N, McMurray J, Caballero L, Stewart S. An epi-demiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30:104-109.
6. Thenappan T, Shah S, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30:1103-1110.
7. Simmoneau G, Robbins I, Beghetti M, et al. Updated clinical classifcation of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43-S54.
8. Badesch D, Raskob G, Elliott C, et al. Pulmonary arterial hypertension - baseline characteristics from the REVEAL registry. Chest. 2010;137:376-387.
9. McLaughlin V, Archer S, Badesch D, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009; 119:2250-2294.
10. Galie N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34: 1219-1263.
11. Farber H, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
12. Christman B, McPherson C, Newman J, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
13. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothe-lin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
14. Stewart D, Levy R, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
15. Tuder R, Cool C, Geraci M, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
16. Rich S, Dantzker D, Ayres S, et al. Primary pulmonary hypertension - a national prospective study. Ann Intern Med. 1987;107:216-223.
17. McGoon M, Gutterman D, Steen V, et al. Screening, early detection and diagnosis of pulmonary arterial hypertension. Chest. 2004;126 Suppl 1: 14S-34S.
18. McQuillan B, Picard M, Leavitt M, Weyman A. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104: 2797-2802.
19. Swan H, Ganz W, Forrester J, Marcu H, Diamond G, Chonette D. Catheterization of the heart in man with use of a fow-directed balloon-tipped catheter. N Engl J Med. 1970;283:447-451.
20. Weiss B, Zemp L, Seifert B, Hess O. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31:1650-1657.
21. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
22. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner H, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112:714-721.
23. Fuster V, Steele P, Edwards W, Gersh B, McGoon M, Frye R. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation. 1984;70:580-587.
24. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998;114:787-792.
25. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.
26. Hickey K, Rubanyi G, Paul R, Highsmith R. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol. 1985;248:C550-C556.
27. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332:411-415.
28. Kedzierski R, Yanagisawa M. Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-876.
29. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120:1562-1569.
30. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2009;3:CD004434.
31. Channick R, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo controlled study. Lancet. 2001; 358:1119-1123.
32. Rubin L, Badesch D, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
33. McLaughlin V, Sitbon O, Badesch B, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-249.
34. Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with frst-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27:589-595.
35. Galie N, Rubin L, Hal-Hiti P, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial. Lancet. 2008;371:2093-2100.
36. Wu C, Chan M, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-a selective antagonist. J Med Chem. 1997;40:1690-1697.
37. Barst R, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169: 441-447.
38. Barst R, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049-2056.
39. Langleben D, Hirsch A, Shalit E, Lezenko L, Barst R. Sustained symptomatic, functional, and hemodynamic beneft with the selective endothelin-a receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension. Chest. 2004;126:1377-1381.
40. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:529-535.
41. Galie N, Olschewski H, Oudiz R, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Circulation. 2008;117:3010-3019.
42. Archer S, Michelakis E. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009;361:1864-1871.
43. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
44. Murray F, MacLean M, Pyne N. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specifc (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol. 2002;137:1187-1194.
45. Galie N, Ghofrani H, Torbicki A, et al. Sildenafl citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353: 2148-2157.
46. Pepke-Zaba J, Gilbert C, Collings L, Brown M. Sildenafl improves health-related quality of life in patients with pulmonary arterial hypertension. Chest. 2008;133:183-189.
47. Galie N, Brundage B, Ghofrani H, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-2903.
48. Zucker T, Bunisch D, Hasse A, Grosser T, Weber A, Schror K. Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol. 1998;345:213-220.
49. Cheng Y, Austin S, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
50. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44:209-214.
51. McLaughlin V, Shilington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation. 2002; 106:1477-1482.
52. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. J Am Coll Cardiol. 2002;40:780-788.
53. Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
54. Badesch D, Tapson V, McGoon M, et al. Continuous intravenous epo-prostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 2000;132:425-434.
55. Aguilar R, Farber H. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000; 162:1846-1850.
56. Plotkin J, Kuo P, Rubin L, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation. 1998;4:457-459.
57. Tan H, Markowitz J, Montgomery R, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl. 2001;7:745-749.
58. Rosenzweig E, Kerstein D, Barst R. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858-1865.
59. Skoro-Sajer N, Lang I, Naeije R. Treprostinil for pulmonary hypertension. Vasc Health Risk Manag. 2008;4:507-513.
60. Simonneau G, Barst R, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:800-804.
61. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129:1636-1643.
62. Barst R, Galie N, Simonneau G, Jeffs R, Arneson C, Rubin L. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Heart J. 2006;28:1195-1203.
63. Tapson V, Gomberg-Maitland M, McLaughlin V, et al. Safety and effcacy of IV treprostinil for pulmonary arterial hypertension. Chest. 2006;129:683-688.
64. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth H. Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag. 2009;5:465-474.
65. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996;124:820-824.
66. Olschewski H, Ghofrani A, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. Ann Intern Med. 2000;132:435-443.
67. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.
68. Hoeper M, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-1870.
69. Opitz C, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J. 2005;26:1895-1902.
70. Galie N, Humbert M, Vachiery J, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo controlled trial. J Am Coll Cardiol. 2002;39:1496-1502.
71. Barst R, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41: 2119-2125.
72. Nagaya N, Uematsu M, Okano Y, et al. Effect of orally active pros-tacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol. 1999;34:1188-1192.
73. Sandifer B, Brigham K, Lawrence E, Mottola D, Cuppels C, Parker R. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J Appl Physiol. 2005;99:2363-2368.
74. Voswinckel R, Ghofrani H, Grimminger F, Seeger W. Inhaled trepro-stinil for treatment of chronic pulmonary arterial hypertension. Ann Intern Med. 2006;144:149-150.
75. Voswinckel R, Enke B, Reichenberger R, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: Results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48: 1672-1681.
76. Channick R, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin L. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48:1433-1437.
77. Voswinckel H, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther. 2008;21:824-832.
78. Voswinckel R, Reichenberger F, Gall H, et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm Pharmacol Ther. 2009;22:50-56.
79. Tyvaso Prescribing Information. Research Triangle Park, NC: United Therapeutics Corp; 2010.